CYTO vs. ATXI, VRPX, ONCO, NTBL, SNOA, SXTP, CWBR, CNSP, SLRX, and CYCC
Should you be buying Altamira Therapeutics stock or one of its competitors? The main competitors of Altamira Therapeutics include Avenue Therapeutics (ATXI), Virpax Pharmaceuticals (VRPX), Onconetix (ONCO), Notable Labs (NTBL), Sonoma Pharmaceuticals (SNOA), 60 Degrees Pharmaceuticals (SXTP), CohBar (CWBR), CNS Pharmaceuticals (CNSP), Salarius Pharmaceuticals (SLRX), and Cyclacel Pharmaceuticals (CYCC). These companies are all part of the "pharmaceutical preparations" industry.
Altamira Therapeutics (NASDAQ:CYTO) and Avenue Therapeutics (NASDAQ:ATXI) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, dividends, earnings, profitability, community ranking, valuation, analyst recommendations, media sentiment and institutional ownership.
1.9% of Altamira Therapeutics shares are owned by institutional investors. Comparatively, 17.3% of Avenue Therapeutics shares are owned by institutional investors. 13.0% of Altamira Therapeutics shares are owned by insiders. Comparatively, 1.8% of Avenue Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Avenue Therapeutics received 147 more outperform votes than Altamira Therapeutics when rated by MarketBeat users.
In the previous week, Altamira Therapeutics and Altamira Therapeutics both had 4 articles in the media. Avenue Therapeutics' average media sentiment score of 1.59 beat Altamira Therapeutics' score of 0.97 indicating that Avenue Therapeutics is being referred to more favorably in the news media.
Altamira Therapeutics has higher revenue and earnings than Avenue Therapeutics.
Altamira Therapeutics has a beta of 1.82, meaning that its share price is 82% more volatile than the S&P 500. Comparatively, Avenue Therapeutics has a beta of -0.09, meaning that its share price is 109% less volatile than the S&P 500.
Summary
Altamira Therapeutics beats Avenue Therapeutics on 5 of the 9 factors compared between the two stocks.
Get Altamira Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for CYTO and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CYTO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Altamira Therapeutics Competitors List
Related Companies and Tools
